Development of hybrid compounds to tackle Alzheimer’s disease

Abstract

Alzheimer’s disease (AD) is the main neurodegenerative disorder worldwide. Its pathogenesis involves a network where various mechanisms are interconnected. This complex pathological network makes it extremely challenging to find an efficacious treatment. Herein, we give an overview on the design of the so-called multi-target-directed ligands, i.e. compounds that concurrently hit several key pathogenic factors within the network, as a realistic option to tackle AD, with a particular emphasis on some structural classes of multitarget hybrids recently developed in our group.